Literature DB >> 25832479

Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma.

Sara De Dosso1, Patrizia Melchiorre, Chiara Della Badia, Giorgio Moschovitis, Piercarlo Saletti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25832479     DOI： 10.1007/s12029-015-9705-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  22 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.

Authors:  J A Maroun; D Jonker; L Seymour; R Goel; M Vincent; W Kocha; C Cripps; B Fisher; D Lister; A Malpage; G Chiritescu
Journal:  Eur J Cancer       Date:  2005-12-05       Impact factor: 9.162

3.  Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.

Authors:  T S Maughan; R D James; D J Kerr; J A Ledermann; C McArdle; M T Seymour; D Cohen; P Hopwood; C Johnston; R J Stephens
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

4.  Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.

Authors:  E Kralidis; S Aebi; H Friess; M W Büchler; M M Borner
Journal:  Ann Oncol       Date:  2003-04       Impact factor: 32.976

Review 5.  Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.

Authors:  Claire Kelly; Neel Bhuva; Mark Harrison; Andrew Buckley; Mark Saunders
Journal:  Eur J Cancer       Date:  2013-04-10       Impact factor: 9.162

6.  5-fluorouracil-induced coronary vasospasm.

Authors:  Laura K Shoemaker; Umesh Arora; Caio M Rocha Lima
Journal:  Cancer Control       Date:  2004 Jan-Feb       Impact factor: 3.302

Review 7.  The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.

Authors:  N C Robben; A W Pippas; J O Moore
Journal:  Cancer       Date:  1993-01-15       Impact factor: 6.860

Review 8.  Cardiotoxicity of 5-fluorouracil.

Authors:  P Alter; M Herzum; M Soufi; J R Schaefer; B Maisch
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2006-01

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

10.  Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

Authors:  M Reni; L Pasetto; G Aprile; S Cordio; E Bonetto; S Dell'Oro; P Passoni; L Piemonti; C Fugazza; G Luppi; C Milandri; R Nicoletti; A Zerbi; G Balzano; V Di Carlo; A A Brandes
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.